Q&A

What helps OCD and intrusive thoughts? The evidence favours a specific therapy

A network meta-analysis of 54 trials put behavioural and cognitive therapies ahead of the drugs on OCD symptoms. But most therapy trials also allowed antidepressants, hinting the two work best together.

Reduction in OCD symptom severity versus placebo (Yale-Brown points; larger = bigger improvement)Behavioural therapy: 14.48points; Cognitive therapy: 13.36points; Cognitive behavioural therapy: 5.37points; Clomipramine: 4.72points; All SSRIs: 3.49points0points10points20pointsBehavioural therapy14.48pointsCognitive therapy13.36pointsCognitive behavioural therapy5.37pointsClomipramine4.72pointsAll SSRIs3.49points
Reduction in OCD symptom severity versus placebo (Yale-Brown points; larger = bigger improvement)
GroupValue (points)
Behavioural therapy14.48 (10.23 to 18.61)
Cognitive therapy13.36 (8.21 to 18.4)
Cognitive behavioural therapy5.37 (1.63 to 9.1)
Clomipramine4.72 (2.6 to 6.85)
All SSRIs3.49 (1.81 to 5.12)
Reduction in OCD symptom severity versus placebo (Yale-Brown points; larger = bigger improvement) Absolute mean differences versus drug placebo on the Yale-Brown Obsessive Compulsive Scale, with 95% credible intervals, from a network meta-analysis of 54 trials. Source: The Lancet Psychiatry

Obsessive-compulsive disorder — the loop of intrusive thoughts and the compulsions people use to neutralise them — responds to two kinds of treatment, and the evidence gives a slight edge to therapy built on facing the fear rather than avoiding it. In the most comprehensive comparison to date, exposure-based behavioural and cognitive therapies produced larger reductions in OCD symptoms than any of the medications [s1]. But a caveat runs through that finding, and it points toward combining the two rather than choosing between them.

The comparison across every option

A 2016 systematic review and network meta-analysis in The Lancet Psychiatry set out to compare all the main OCD treatments at once, using both direct and indirect evidence [s1]. From 1,480 articles the reviewers included 53 papers reporting 54 trials with 6,652 participants, and measured everything on the same yardstick: change in the Yale-Brown Obsessive Compulsive Scale, reported as the mean difference against placebo [s1].

The ordering was striking. Behavioural therapy showed the largest effect (mean difference -14.48, 95% credible interval -18.61 to -10.23; 11 trials, 287 patients), followed by cognitive therapy (-13.36; six trials, 172 patients) [s1]. The drug-based options were more modest: cognitive behavioural therapy came in at -5.37 (nine trials, 231 patients), clomipramine at -4.72 (13 trials, 831 patients) and the SSRIs as a class at -3.49 (37 trials, 3,158 patients) [s1]. Larger negative numbers mean bigger symptom reductions. Clomipramine — the older tricyclic long regarded as the strongest OCD drug — was not statistically better than the SSRIs (-1.23, 95% CrI -3.41 to 0.94) [s1].

Why "therapy wins" is too simple

The tempting headline is that therapy beats medication. The reviewers themselves flagged why that overstates it. In 12 of the 15 psychotherapy trials — 80% of them — participants were allowed to keep taking stable doses of antidepressants [s1]. So the impressive therapy numbers were often measured in people who were already medicated, which makes the therapy-versus-drug contrast partly a therapy-plus-drug versus drug-alone contrast. Their considered conclusion was that combining psychotherapeutic and pharmacological treatment is likely to be more effective than psychotherapy alone, at least in severe OCD [s1].

What the therapy actually is

The behavioural therapy carrying those large effects is exposure and ritual (or response) prevention: deliberately confronting the triggering thought or situation while resisting the compulsion, until the anxiety subsides on its own. A landmark 2005 randomised, placebo-controlled trial shows how strong that can be [s2]. Among 122 adults with OCD assigned to exposure and ritual prevention, clomipramine, their combination, or placebo, response rates among those who completed treatment were 86% for exposure and ritual prevention, 79% for the combination, 48% for clomipramine and 10% for placebo [s2]. Counting everyone treated, the figures were 62%, 70%, 42% and 8% respectively [s2]. Exposure and ritual prevention matched its own combination with the drug and beat clomipramine alone [s2]. The trial's exposure course was intensive — daily sessions for four weeks, then eight weekly maintenance visits — while clomipramine was titrated to a maximum of 250 mg a day over 12 weeks [s2]. That intensity is a real caveat: the therapy is demanding to deliver and to complete, which is part of why access to it remains patchy even though the evidence is strong.

What it means

For someone living with intrusive thoughts and compulsions, the evidence points to a clear plan. Exposure and ritual prevention is the best-supported psychological treatment and belongs at the centre of care; an SSRI (or clomipramine) is a well-evidenced option, especially for people who cannot access or tolerate the therapy; and for more severe OCD the combination has the strongest rationale [s1][s2]. Two practical points follow from the trial data: the therapy has to include the ritual-prevention part, not just talking about the thoughts, and completing a full course matters — the biggest response rates were among people who finished [s2].

One reassurance is worth stating plainly: intrusive thoughts, including violent or taboo ones, are a symptom of the disorder, not a sign of what someone secretly wants, and they do not mean a person is dangerous. OCD is treatable, and anyone whose thoughts or rituals are dominating their day — or who is having thoughts of self-harm — should speak to a GP or mental health professional. This article describes evidence and is not medical advice.

Sources

Sources

  1. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis — The Lancet Psychiatry , June 16, 2016
  2. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder — The American Journal of Psychiatry , January 1, 2005

More on

Related coverage